novo nordisk obesity drug - Search News

Novo Nordisk Shares Fall

Data on new Novo Nordisk obesity drug disappoints in trial, shares drop

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.

The Wall Street Journal on MSN · 1d

Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an earlier study recorded 22.7%.

Novo Nordisk shares drop after next-gen obesity drug disappoints in diabetes trial

Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that fell short of investors’ expectations.

Roche, Zealand Pharma and obesity

Reuters on MSN · 58m

Roche secures Zealand obesity drug candidate for up to $5.3 billion

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects in the booming weight-loss market.

MarketWatch · 37m

Zealand Pharma Shares Leap After Weight-Loss Licensing Deal With Roche

Zealand Pharma shares rose sharply after the Danish pharmaceutical company struck a licensing and collaboration deal of up to $5.3 billion with Roche. Shares in Zealand were up 25% at 609 Danish kroner in European morning trading Wednesday,

Bloomberg · 2h

Roche, Zealand Pharma in $5.3 Billion Pact for Obesity Drugs

Roche Holding AG licensed a new weight-loss drug from Zealand Pharma A/S for as much as $5.3 billion, bolstering the Swiss drugmaker’s effort to get into a hot market dominated by Novo Nordisk A/S and Eli Lilly & Co.

Pharmaceutical Technology on MSN12h

Viking strikes $150m deal to secure supply of obesity drug

Viking Therapeutics has inked a $150m multi-year manufacturing deal with CordenPharma to secure the future supply of its ...

3don MSN

Weight-loss drug battle: Who are the latest players involved

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

5don MSN

Popular weight-loss drugs get cheaper: Novo Nordisk and Eli Lilly cut prices

Danish drugmaker Novo Nordisk said Wednesday that it will drop prices 23% for all doses of Wegovy. The new monthly price of ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results